menu ☰
menu ˟

Oyster Point's dry eye treatment shows positive phase 2b trial results

12 Jul 2018
Oyster Point Pharma’s dry eye disease treatment met both sign and symptom primary endpoints in a phase 2b clinical trial, the company announced in a press release.OC-02, a nicotinic acetylcholine receptor agonist, is delivered as a nasal spray and ...

Click here to view the full article which appeared in Opthalmology

IPH Logo